Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Licenses Canadian Rights to miRNA Diagnostics to Warnex

Premium

Rosetta Genomics said this week that it has signed a deal making Warnex Medical Laboratories the exclusive distributor of Rosetta's three microRNA-based diagnostics in Canada.

Under the deal, Warnex will market Rosetta's miRview Meso, which differentiates lung cancer from mesothelioma; miRview Mets, which is designed to determine the source of cancers of unknown primary origin; and miRview Squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer.

The company will send tissue samples from its Canadian customers to Rosetta's Philadelphia-based lab for analysis.

Additional terms of the deal were not disclosed.

Rosetta has long been on the lookout for marketing partners for its miRNA tests. In April, it signed a deal giving Prometheus Laboratories the US rights to the three diagnostics (see RNAi News, 4/16/2009). In January, it licensed the Israeli and Turkish rights to Teva Pharmaceuticals (see RNAi News, 1/8/2009).

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more